Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.52 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | GSK3B | P49841 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.46 |
| ▸ | MAT2A | P31153 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590692 | 0.89 | ALDH1A1 (0.47) | ROCK2JAK2GSK3BMEN1RAB9A | |
| SCHEMBL3200472 | 0.81 | L3MBTL1 (0.50) | ROCK2JAK2GSK3BPOLBMEN1 | |
| SCHEMBL3200462 | 0.81 | L3MBTL1 (0.50) | ROCK2JAK2GSK3BPOLBMEN1 | |
| SCHEMBL4591056 | 0.81 | L3MBTL1 (0.50) | ROCK2JAK2GSK3BPOLBMEN1 | |
| SCHEMBL3189171 | 0.80 | ROCK2 (0.45) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL3189413 | 0.80 | ROCK2 (0.45) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL3189403 | 0.80 | ROCK2 (0.45) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL3189178 | 0.80 | ROCK2 (0.45) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL3178727 | 0.80 | ROCK2 (0.45) | ROCK2JAK2GSK3BCYP2D6SLC6A2 | |
| SCHEMBL5922787 | 0.78 | ROCK2 (0.41) | ROCK2JAK2GSK3BCYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379249-A4 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-01-09 | — | — | EP | claimed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | claimed |
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | claimed |
| EP-1379249-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002067939-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ROCK2 4658/4885JAK2 2800/4885GSK3B 3296/4885 |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ROCK2 4658/4885JAK2 2800/4885GSK3B 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.